Skip to content

Study · Observational study · 2026

5 results

Cerebrolysin after Endovascular Thrombectomy in Stroke: 12‑Month Functional Outcomes in a Propensity‑Matched Cohort.

Staszewski J, Dębiec A, Gniadek-Olejniczak K, Stępień A, Piusinska-Macoch R, Strilciuc S, Balo D, Harston G, Brzozowski K, Zięcina P, Narloch J, Wierzbicki M, Piasecki P

Translational stroke research25 Feb 2026

PMID41739286 (opens in a new tab)PMCIDPMC12935719 (opens in a new tab)DOI10.1007/s12975-026-01414-z (opens in a new tab)PepBankPUB-41739286
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In EVT-treated stroke patients, Cerebrolysin was linked to higher adjusted odds of functional independence at 12 months than historical controls.

    In plain wordsIn stroke patients after EVT, Cerebrolysin was linked to greater independence at 12 months than historical controls.

    Peptide
    Cerebrolysin
    Outcome
    Increase12-month functional independence
    Study

    n: not reported in source

    Comparator
    historical controls
    Analysis
    Primary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL/day · 21 days, with a second 21-day course at 69-90 daysAs given in this study (human).

    Measurements

    Adjusted odds ratio
    6.1
    reported result
    95% CI
    1.64 to 22.66
    reported result
    p value for adjusted odds of 12-month functional independence
    < 0.01
    Cerebrolysin versus historical controls, adjusted association at 12 months

    Source sentences

    Summary
    Results Cerebrolysin use was associated with higher odds of 12-month functional independence after adjustment for potential confounders (aOR 6.10, 95% CI 1.64-22.66; p<0.01)
    3 context sentences
    Summary · context
    The primary endpoint was functional independence (modified Rankin Scale [mRS] 0-2) at 12 months.
    Summary · context
    Methods Consecutive EVT patients were prospectively enrolled and treated with Cerebrolysin 30 mL/day for 21 days starting immediately post-EVT, with a second 21-day course at 69-90 days.
    Summary · context
    Outcomes were compared with historical controls using 1:1 nearest-neighbor propensity score matching on ten prespecified covariates.
  2. 02HumanObservational studyEfficacy outcome

    In EVT-treated stroke patients, Cerebrolysin was linked to a favorable shift toward lower disability at 12 months than historical controls.

    In plain wordsIn stroke patients after EVT, Cerebrolysin was linked to lower disability at 12 months than historical controls.

    Peptide
    Cerebrolysin
    Outcome
    Decrease12-month mRS shift
    Study

    n: not reported in source

    Comparator
    historical controls
    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL/day · 21 days, with a second 21-day course at 69-90 daysAs given in this study (human).

    Measurements

    Common odds ratio
    3.57
    reported result
    95% CI
    1.42 to 8.93
    reported result
    p value for favorable 12-month mRS shift
    < 0.01
    Cerebrolysin versus historical controls, common odds ratio for favorable shift at 12 months

    Source sentences

    Summary
    and a favorable shift toward lower disability across the 12-month mRS distribution (common OR for favorable shift 3.57, 95% CI 1.42-8.93; p<0.01).
    2 context sentences
    Summary · context
    Methods Consecutive EVT patients were prospectively enrolled and treated with Cerebrolysin 30 mL/day for 21 days starting immediately post-EVT, with a second 21-day course at 69-90 days.
    Summary · context
    Outcomes were compared with historical controls using 1:1 nearest-neighbor propensity score matching on ten prespecified covariates.
  3. 03HumanObservational studyEfficacy outcome

    Among EVT-treated stroke survivors, institutional care was needed by 6% with Cerebrolysin versus 19% of historical controls.

    In plain wordsAmong stroke survivors after EVT, 6% with Cerebrolysin versus 19% of historical controls needed institutional care.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseInstitutional care among survivors
    Study

    n: not reported in source

    Comparator
    historical controls
    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL/day · 21 days, with a second 21-day course at 69-90 daysAs given in this study (human).

    Measurements

    Unadjusted odds ratio
    0.26
    reported result
    95% CI
    0.07 to 0.99
    reported result
    NNT
    8
    reported result
    Institutional care
    6%
    Cerebrolysin group, among survivors
    Institutional care
    19%
    historical controls, among survivors

    Source sentences

    Summary
    Among survivors, 6% of the Cerebrolysin group versus 19% of controls required institutional care (unadjusted OR 0.26; 95% CI 0.07-0.99; NNT 8).
    2 context sentences
    Summary · context
    Methods Consecutive EVT patients were prospectively enrolled and treated with Cerebrolysin 30 mL/day for 21 days starting immediately post-EVT, with a second 21-day course at 69-90 days.
    Summary · context
    Outcomes were compared with historical controls using 1:1 nearest-neighbor propensity score matching on ten prespecified covariates.
  4. 04HumanObservational studyEfficacy outcome

    In EVT-treated stroke patients, Barthel Index scores were higher with Cerebrolysin than historical controls, with medians of 92 versus 83.

    In plain wordsIn stroke patients after EVT, daily activity scores were higher with Cerebrolysin than historical controls.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarthel Index
    Study

    n: not reported in source

    Comparator
    historical controls
    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL/day · 21 days, with a second 21-day course at 69-90 daysAs given in this study (human).

    Measurements

    Barthel Index median (Q1-Q3 82-100)
    92
    Cerebrolysin group
    Barthel Index median (Q1-Q3 73-93)
    83
    controls
    Barthel Index Q1-Q3
    82 to 100
    Cerebrolysin group
    Barthel Index Q1-Q3
    73 to 93
    historical controls
    p value for Barthel Index scores
    0.01
    Cerebrolysin group versus historical controls

    Source sentences

    Summary
    BI scores were higher in the Cerebrolysin group than in controls (median (Q1-Q3) 92 (82-100) vs 83 (73-93); p=0.01).
    2 context sentences
    Summary · context
    Methods Consecutive EVT patients were prospectively enrolled and treated with Cerebrolysin 30 mL/day for 21 days starting immediately post-EVT, with a second 21-day course at 69-90 days.
    Summary · context
    Outcomes were compared with historical controls using 1:1 nearest-neighbor propensity score matching on ten prespecified covariates.
  5. 05HumanObservational studySafety outcome

    In EVT-treated stroke patients, cumulative mortality was similar with Cerebrolysin and historical controls, at 18% in both groups.

    In plain wordsIn stroke patients after EVT, mortality was similar with Cerebrolysin and historical controls, at 18% in both groups.

    Peptide
    Cerebrolysin
    Outcome
    No significant change12-month mortality
    Study

    n: not reported in source

    Comparator
    historical controls
    Outcome group
    Mortality · Whole body
    Studied dose
    30 mL/day · 21 days, with a second 21-day course at 69-90 daysAs given in this study (human).

    Measurements

    Cumulative 12-month mortality
    18%
    Cerebrolysin group
    Cumulative 12-month mortality
    18%
    historical controls

    Source sentences

    Summary
    Cumulative 12-month mortality was similar between groups (both 18%).
    2 context sentences
    Summary · context
    Methods Consecutive EVT patients were prospectively enrolled and treated with Cerebrolysin 30 mL/day for 21 days starting immediately post-EVT, with a second 21-day course at 69-90 days.
    Summary · context
    Outcomes were compared with historical controls using 1:1 nearest-neighbor propensity score matching on ten prespecified covariates.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.